ARACHCHIGE MUTHUKUDA: Open Payments
NPI 1073770616 · BALTIMORE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$531 in 18 payments from 8 companies in 2025. Trend: 2023 $32 · 2024 $22 · 2025 $531
Food & beverage: $431Education: $100
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 4 | $126 |
| Teva Pharmaceuticals USA, Inc. | 2 | $120 |
| Vanda Pharmaceuticals Inc. | 2 | $74 |
| E.R. Squibb & Sons, L.L.C. | 4 | $65 |
| Axsome Therapeutics, Inc. | 2 | $54 |
| Lundbeck LLC | 2 | $37 |
| Janssen Pharmaceuticals, Inc | 1 | $30 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $25 |
Products named: INGREZZA, FANAPT, COBENFY, Auvelity, INVEGA SUSTENNA, CAPLYTA, UZEDY, ABILIFY ASIMTUFII.
Industry payments across MD — which companies pay providers there.
